Prognostic Value of Neutrophil-to-Lymphocyte Ratio Following Chemoradiation Therapy for Stage III Non–small Cell Lung Cancer

MLA

Nitin Ohri, et al. “Prognostic Value of Neutrophil-to-Lymphocyte Ratio Following Chemoradiation Therapy for Stage III Non–small Cell Lung Cancer.” International Journal of Radiation Oncology*Biology*Physics, vol. 99, Oct. 2017, pp. E451–52. EBSCOhost, https://doi.org/10.1016/j.ijrobp.2017.06.1684.

APA

Nitin Ohri, Chandan Guha, S.C. Desai, K. O’Grady, Shalom Kalnicki, Madhur Garg, & W.R. Bodner. (2017). Prognostic Value of Neutrophil-to-Lymphocyte Ratio Following Chemoradiation Therapy for Stage III Non–small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics, 99, E451–E452. https://doi.org/10.1016/j.ijrobp.2017.06.1684

Chicago

Nitin Ohri, Chandan Guha, S.C. Desai, K. O’Grady, Shalom Kalnicki, Madhur Garg, and W.R. Bodner. 2017. “Prognostic Value of Neutrophil-to-Lymphocyte Ratio Following Chemoradiation Therapy for Stage III Non–small Cell Lung Cancer.” International Journal of Radiation Oncology*Biology*Physics 99 (October): E451–52. doi:10.1016/j.ijrobp.2017.06.1684.